{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:08:51Z","timestamp":1785863331475,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s40266-017-0512-4","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T09:36:58Z","timestamp":1512553018000},"page":"873-880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Managing Gout Flares in the Elderly: Practical Considerations"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0121-4919","authenticated-orcid":false,"given":"Abhishek","family":"Abhishek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,12,6]]},"reference":[{"key":"512_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204463","author":"C-F Kuo","year":"2014","unstructured":"Kuo C-F, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2014. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2013-204463\n                        \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"512_CR2","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1002\/art.30520","volume":"63","author":"Y Zhu","year":"2011","unstructured":"Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008. Arthritis Rheum. 2011;63(10):3136\u201341. \n                        https:\/\/doi.org\/10.1002\/art.30520\n                        \n                    .","journal-title":"Arthritis Rheum"},{"key":"512_CR3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.7326\/0003-4819-54-3-452","volume":"54","author":"DJ McCarty","year":"1961","unstructured":"McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. 1961;54:452\u201360.","journal-title":"Ann Intern Med"},{"issue":"10","key":"512_CR4","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/acr.22855","volume":"68","author":"A Abhishek","year":"2016","unstructured":"Abhishek A, Valdes AM, Zhang W, Doherty M. Association of serum uric acid and disease duration with frequent gout attacks: a case-control study. Arthritis Care Res. 2016;68(10):1573\u20137. \n                        https:\/\/doi.org\/10.1002\/acr.22855\n                        \n                    .","journal-title":"Arthritis Care Res."},{"issue":"8","key":"512_CR5","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/art.39684","volume":"68","author":"J Poiley","year":"2016","unstructured":"Poiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, et al. A Randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol (Hoboken, NJ). 2016;68(8):2027\u201334. \n                        https:\/\/doi.org\/10.1002\/art.39684\n                        \n                    .","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"issue":"3","key":"512_CR6","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3899\/jrheum.161062","volume":"44","author":"AS Steinberg","year":"2017","unstructured":"Steinberg AS, Vince BD, Choi YJ, Martin RL, McWherter CA, Boudes PF. The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout. J Rheumatol. 2017;44(3):374\u20139. \n                        https:\/\/doi.org\/10.3899\/jrheum.161062\n                        \n                    .","journal-title":"J Rheumatol"},{"key":"512_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-016-1062-6","author":"M Dehlin","year":"2016","unstructured":"Dehlin M, Drivelegka P, Sigurdardottir V, Sv\u00e4rd A, Jacobsson LTH. Incidence and prevalence of gout in Western Sweden. Arthritis Res Ther. 2016. \n                        https:\/\/doi.org\/10.1186\/s13075-016-1062-6\n                        \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"512_CR8","first-page":"71","volume":"21","author":"AN Atallah","year":"1988","unstructured":"Atallah AN, Guimaraes JA, Gebara M, Sustovich DR, Martinez TR, Camano L. Progesterone increases glomerular filtration rate, urinary kallikrein excretion and uric acid clearance in normal women. Braz J Med Biol Res Revista brasileira de pesquisas medicas e biologicas. 1988;21(1):71\u20134.","journal-title":"Braz J Med Biol Res Revista brasileira de pesquisas medicas e biologicas."},{"issue":"5851","key":"512_CR9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/bmj.1.5851.449","volume":"1","author":"A Nicholls","year":"1973","unstructured":"Nicholls A, Snaith ML, Scott JT. Effect of oestrogen therapy on plasma and urinary levels of uric acid. BMJ. 1973;1(5851):449\u201351.","journal-title":"BMJ"},{"issue":"7","key":"512_CR10","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/ard.2009.109884","volume":"69","author":"AE Hak","year":"2010","unstructured":"Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69(7):1305\u20139. \n                        https:\/\/doi.org\/10.1136\/ard.2009.109884\n                        \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"512_CR11","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/rheumatology\/keq363","volume":"50","author":"D Rothenbacher","year":"2011","unstructured":"Rothenbacher D, Primatesta P, Ferreira A, Cea-Soriano L, Rodriguez LA. Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxf Engl). 2011;50(5):973\u201381. \n                        https:\/\/doi.org\/10.1093\/rheumatology\/keq363\n                        \n                    .","journal-title":"Rheumatology (Oxf Engl)"},{"issue":"1","key":"512_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","volume":"74","author":"P Richette","year":"2015","unstructured":"Richette P, Clerson P, P\u00e9rissin L, Flipo R-M, Bardin T. Revisiting comorbidities in gout: a cluster analysis. Ann Rheum Dis. 2015;74(1):142\u20137. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2013-203779\n                        \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"512_CR13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/ard.46.1.72","volume":"46","author":"EJ Borg ter","year":"1987","unstructured":"ter Borg EJ, Rasker JJ. Gout in the elderly, a separate entity? Ann Rheum Dis. 1987;46(1):72\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"512_CR14","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0002-9343(74)90639-1","volume":"56","author":"NM Hadler","year":"1974","unstructured":"Hadler NM, Franck WA, Bress NM, Robinson DR. Acute polyarticular gout. Am J Med. 1974;56(5):715\u20139.","journal-title":"Am J Med"},{"issue":"4","key":"512_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1532-5415.2008.01619.x","volume":"56","author":"B Getta","year":"2008","unstructured":"Getta B, O\u2019Mahony PG. Atypical presentation of acute gout in an elderly patient. J Am Geriatr Soc. 2008;56(4):764\u20135. \n                        https:\/\/doi.org\/10.1111\/j.1532-5415.2008.01619.x\n                        \n                    .","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"512_CR16","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/RHU.0b013e318293794f","volume":"19","author":"ME Wilson","year":"2013","unstructured":"Wilson ME, Wan SH, Beyder A, Osborn TG, Beckman TJ. Acute polyarticular gout presenting as delirium. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2013;19(4):221\u20132. \n                        https:\/\/doi.org\/10.1097\/RHU.0b013e318293794f\n                        \n                    .","journal-title":"J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis."},{"issue":"10","key":"512_CR17","doi-asserted-by":"publisher","first-page":"e0186096","DOI":"10.1371\/journal.pone.0186096","volume":"12","author":"A Abhishek","year":"2017","unstructured":"Abhishek A, Valdes AM, Jenkins W, Zhang W, Doherty M. Triggers of acute attacks of gout, does age of gout onset matter? A primary care based cross-sectional study. PLoS One. 2017;12(10):e0186096. \n                        https:\/\/doi.org\/10.1371\/journal.pone.0186096\n                        \n                    .","journal-title":"PLoS One"},{"key":"512_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-016-0936-y","volume":"18","author":"JA Singh","year":"2016","unstructured":"Singh JA, Yu S. Gout-related inpatient utilization: a study of predictors of outcomes and time trends. Arthritis Res Ther. 2016;18:57. \n                        https:\/\/doi.org\/10.1186\/s13075-016-0936-y\n                        \n                    .","journal-title":"Arthritis Res Ther."},{"key":"512_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1254-8","author":"W He","year":"2017","unstructured":"He W, Phipps-Green A, Stamp LK, Merriman TR, Dalbeth N. Population-specific association between ABCG2 variants and tophaceous disease in people with gout. Arthritis Res Ther. 2017. \n                        https:\/\/doi.org\/10.1186\/s13075-017-1254-8\n                        \n                    .","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"512_CR20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/24.2.155","volume":"24","author":"DG Macfarlane","year":"1985","unstructured":"Macfarlane DG, Dieppe PA. Diuretic-induced gout in elderly women. Br J Rheumatol. 1985;24(2):155\u20137.","journal-title":"Br J Rheumatol"},{"issue":"7","key":"512_CR21","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/rheumatology\/kew018","volume":"55","author":"S Mitnala","year":"2016","unstructured":"Mitnala S, Phipps-Green A, Franklin C, Horne A, Stamp LK, Merriman TR, et al. Clinical and genetic features of diuretic-associated gout: a case-control study. Rheumatology. 2016;55(7):1172\u20136. \n                        https:\/\/doi.org\/10.1093\/rheumatology\/kew018\n                        \n                    .","journal-title":"Rheumatology"},{"issue":"1","key":"512_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.7861\/clinmedicine.17-1-54","volume":"17","author":"A Abhishek","year":"2017","unstructured":"Abhishek A, Roddy E, Doherty M. Gout - a guide for the general and acute physicians. Clin Med (Lond). 2017;17(1):54\u20139. \n                        https:\/\/doi.org\/10.7861\/clinmedicine.17-1-54\n                        \n                    .","journal-title":"Clin Med (Lond)."},{"issue":"8","key":"512_CR23","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxf Engl). 2007;46(8):1372\u20134. \n                        https:\/\/doi.org\/10.1093\/rheumatology\/kem056a\n                        \n                    .","journal-title":"Rheumatology (Oxf Engl)"},{"issue":"11","key":"512_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.56.11.696a","volume":"56","author":"JA Logan","year":"1997","unstructured":"Logan JA, Morrison E, McGILL PE. Serum uric acid in acute gout. Ann Rheum Dis. 1997;56(11):696\u20137. \n                        https:\/\/doi.org\/10.1136\/ard.56.11.696a\n                        \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"512_CR25","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.berh.2012.09.003","volume":"26","author":"N Dalbeth","year":"2012","unstructured":"Dalbeth N, Doyle AJ. Imaging of gout: an overview. Best Pract Res Clin Rheumatol. 2012;26(6):823\u201338. \n                        https:\/\/doi.org\/10.1016\/j.berh.2012.09.003\n                        \n                    .","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"512_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.7326\/m16-0462","volume":"166","author":"SJ Newberry","year":"2017","unstructured":"Newberry SJ, FitzGerald JD, Motala A, Booth M, Maglione MA, Han D, et al. Diagnosis of gout: a systematic review in support of an american college of physicians clinical practice guideline. Ann Intern Med. 2017;166(1):27\u201336. \n                        https:\/\/doi.org\/10.7326\/m16-0462\n                        \n                    .","journal-title":"Ann Intern Med"},{"issue":"3","key":"512_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3899\/jrheum.140634","volume":"42","author":"C Loffler","year":"2015","unstructured":"Loffler C, Sattler H, Peters L, Loffler U, Uppenkamp M, Bergner R. Distinguishing gouty arthritis from calcium pyrophosphate disease and other arthritides. J Rheumatol. 2015;42(3):513\u201320. \n                        https:\/\/doi.org\/10.3899\/jrheum.140634\n                        \n                    .","journal-title":"J Rheumatol"},{"issue":"4 Suppl 98","key":"512_CR28","first-page":"32","volume":"34","author":"A Abhishek","year":"2016","unstructured":"Abhishek A, Doherty M. Update on calcium pyrophosphate deposition. Clin Exp Rheumatol. 2016;34(4 Suppl 98):32\u20138.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"512_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.rdc.2014.01.011","volume":"40","author":"HK Ea","year":"2014","unstructured":"Ea HK, Liote F. Diagnosis and clinical manifestations of calcium pyrophosphate and basic calcium phosphate crystal deposition diseases. Rheum Dis Clin North Am. 2014;40(2):207\u201329. \n                        https:\/\/doi.org\/10.1016\/j.rdc.2014.01.011\n                        \n                    .","journal-title":"Rheum Dis Clin North Am"},{"key":"512_CR30","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7326\/0003-4819-56-5-738","volume":"56","author":"NN Kohn","year":"1962","unstructured":"Kohn NN, Hughes RE, Mc CD Jr, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the \u201cpseudogout syndrome\u201d. II. Identification of crystals. Ann Intern Med. 1962;56:738\u201345.","journal-title":"Ann Intern Med"},{"issue":"2","key":"512_CR31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/rheumatology\/23.2.84","volume":"23","author":"PA Dieppe","year":"1984","unstructured":"Dieppe PA, Doherty M, Macfarlane DG, Hutton CW, Bradfield JW, Watt I. Apatite associated destructive arthritis. Br J Rheumatol. 1984;23(2):84\u201391.","journal-title":"Br J Rheumatol"},{"issue":"10","key":"512_CR32","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447\u201361. \n                        https:\/\/doi.org\/10.1002\/acr.21773\n                        \n                    .","journal-title":"Arthritis Care Res."},{"issue":"1","key":"512_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Casta\u00f1eda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707\n                        \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"512_CR34","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/art.30389","volume":"63","author":"RA Terkeltaub","year":"2011","unstructured":"Terkeltaub RA, Furst DE, DiGiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4\/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226\u201337. \n                        https:\/\/doi.org\/10.1002\/art.30389\n                        \n                    .","journal-title":"Arthritis Rheum"},{"issue":"4","key":"512_CR35","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","volume":"62","author":"RA Terkeltaub","year":"2010","unstructured":"Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060\u20138. \n                        https:\/\/doi.org\/10.1002\/art.27327\n                        \n                    .","journal-title":"Arthritis Rheum"},{"issue":"12","key":"512_CR36","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s40261-014-0238-6","volume":"34","author":"S Wason","year":"2014","unstructured":"Wason S, Mount D, Faulkner R. Single-dose, open-label study of the differences in pharmacokinetics of colchicine in subjects with renal impairment, including end-stage renal disease. Clin Drug Investig. 2014;34(12):845\u201355. \n                        https:\/\/doi.org\/10.1007\/s40261-014-0238-6\n                        \n                    .","journal-title":"Clin Drug Investig."},{"key":"512_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009920.pub2","author":"MD Wechalekar","year":"2013","unstructured":"Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev. 2013. \n                        https:\/\/doi.org\/10.1002\/14651858.CD009920.pub2\n                        \n                    .","journal-title":"Cochrane Database Syst Rev."},{"issue":"5","key":"512_CR38","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","volume":"49","author":"CY Man","year":"2007","unstructured":"Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med. 2007;49(5):670\u20137. \n                        https:\/\/doi.org\/10.1016\/j.annemergmed.2006.11.014\n                        \n                    .","journal-title":"Ann Emerg Med"},{"issue":"9627","key":"512_CR39","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/s0140-6736(08)60799-0","volume":"371","author":"HJ Janssens","year":"2008","unstructured":"Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet (Lond Engl). 2008;371(9627):1854\u201360. \n                        https:\/\/doi.org\/10.1016\/s0140-6736(08)60799-0\n                        \n                    .","journal-title":"Lancet (Lond Engl)"},{"key":"512_CR40","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2318-12-11","volume":"12","author":"RL Jackson","year":"2012","unstructured":"Jackson RL, Hunt B, MacDonald PA. The efficacy and safety of febuxostat for urate lowering in gout patients \u226565\u00a0years of age. BMC Geriatr. 2012;12:11. \n                        https:\/\/doi.org\/10.1186\/1471-2318-12-11\n                        \n                    .","journal-title":"BMC Geriatr."},{"issue":"9","key":"512_CR41","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"LK Stamp","year":"2017","unstructured":"Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522\u20138. \n                        https:\/\/doi.org\/10.1136\/annrheumdis-2016-210872\n                        \n                    .","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"512_CR42","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47\u201356.","journal-title":"Am J Med."},{"issue":"Suppl 3","key":"512_CR43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/annrheumdis-2012-eular.2860","volume":"71","author":"BE Lavan","year":"2013","unstructured":"Lavan BE, McWherter C, Choi YJ. Arhalofenate, a novel uricosuric agent, is an inhibitor of human uric acid transporters [abstract]. Ann Rheum Dis. 2013;71(Suppl 3):450\u20131.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"512_CR44","first-page":"S697","volume":"64","author":"YJ Choi","year":"2012","unstructured":"Choi YJ, Larroca V, Lucman A, Vicena V, Abarca N, Rantz T. Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties [abstract]. Arthritis Rheum. 2012;64(Suppl):S697.","journal-title":"Arthritis Rheum"},{"issue":"7081","key":"512_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341. \n                        https:\/\/doi.org\/10.1038\/nature04516\n                        \n                    .","journal-title":"Nature"},{"issue":"1","key":"512_CR46","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","volume":"18","author":"J Miner","year":"2016","unstructured":"Miner J, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, et al. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res Ther. 2016;18(1):214. \n                        https:\/\/doi.org\/10.1186\/s13075-016-1107-x\n                        \n                    .","journal-title":"Arthritis Res Ther."},{"issue":"6","key":"512_CR47","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9343(03)00436-4","volume":"115","author":"R Segal","year":"2003","unstructured":"Segal R, Lubart E, Leibovitz A, Berkovitch M, Habot B, Yaron M, et al. Early and late effects of low-dose aspirin on renal function in elderly patients. Am J Med. 2003;115(6):462\u20136.","journal-title":"Am J Med."},{"issue":"1","key":"512_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/1529-0131(200001)43:1<103::aid-anr13>3.0.co;2-c","volume":"43","author":"D Caspi","year":"2000","unstructured":"Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103\u20138. \n                        https:\/\/doi.org\/10.1002\/1529-0131(200001)43:1<103:aid-anr13>3.0.co;2-c\n                        \n                    .","journal-title":"Arthritis Rheum"},{"key":"512_CR49","doi-asserted-by":"publisher","first-page":"d8190","DOI":"10.1136\/bmj.d8190","volume":"344","author":"HK Choi","year":"2012","unstructured":"Choi HK, Soriano LC, Zhang Y, Rodr\u00edguez LAG. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012;344:d8190. \n                        https:\/\/doi.org\/10.1136\/bmj.d8190\n                        \n                    .","journal-title":"BMJ"},{"issue":"1","key":"512_CR50","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.33315","volume":"64","author":"MA McAdams DeMarco","year":"2012","unstructured":"McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum. 2012;64(1):121\u20139. \n                        https:\/\/doi.org\/10.1002\/art.33315\n                        \n                    .","journal-title":"Arthritis Rheum"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-017-0512-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-017-0512-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T22:59:10Z","timestamp":1513205950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-017-0512-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["512"],"URL":"https:\/\/doi.org\/10.1007\/s40266-017-0512-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}